Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lobe Sciences Ltd Ordinary Shares GTSIF

Healthcare Drug Manufacturers - Specialty & Generic
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Recent & Breaking News (OTCPK:GTSIF)

CSE Bulletin: New Listing - Glenstar Ventures Inc. (GSTR)

Newsfile July 23, 2024

Lobe Sciences, Ltd. Provides Update on Vitamind

Newsfile April 21, 2023

Lobe Sciences Ltd. (CSE:LOBE) to acquire Altemia & Company

Jocelyn Aspa April 18, 2023

Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

Newsfile April 18, 2023

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Newsfile April 4, 2023

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Newsfile March 22, 2023

Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!

TheNewsWire March 1, 2023

A small-cap psychedelics company is set to change the way neurological disorders are treated

Jocelyn Aspa February 21, 2023

Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC

Newsfile February 21, 2023

Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance

Newsfile February 10, 2023

Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA

Newsfile February 6, 2023

Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

Newsfile January 26, 2023

Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees

Newsfile January 23, 2023

Lobe Sciences Provides Update For 2023 Milestones

Newsfile January 18, 2023

Lobe Sciences (CSE:LOBE) advances clinical development plans for its proprietary psilocin product

Jonathon Brown November 30, 2022

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Newsfile November 30, 2022

Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022

Newsfile November 8, 2022

Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Newsfile October 13, 2022

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Newsfile October 5, 2022

Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings

Newsfile October 3, 2022